Business context and reporting period
The provided Form 10-K is for HealthCor Catalio Acquisition Corp., not Hyperfine, Inc. It covers the period from incorporation on November 18, 2020 through December 31, 2020, and was filed March 26, 2021. The company was a Cayman Islands blank-check company formed to pursue an initial business combination, with a stated focus on healthcare businesses in the United States and other developed countries. It had not selected or contacted a specific target as of the filing.
The company had no operating business, employees, operating revenue, or publicly traded Class A shares at December 31, 2020. Its Class A shares began trading on Nasdaq in January 2021 under the symbol HCAQ.
Financial metrics and liquidity
| Metric | Period-end or period result |
|---|---|
| Operating revenue | $0 |
| Net loss | $5,000 for November 18–December 31, 2020 |
| Basic and diluted loss per share | Approximately $0.00 |
| Cash | $0 at December 31, 2020 |
| Total assets | $304,412, consisting entirely of deferred offering costs |
| Current liabilities | $284,412, including $246,037 of accrued offering costs and a $38,375 related-party promissory note |
| Shareholders’ equity | $20,000 |
| Debt | No long-term debt; $38,375 related-party promissory note outstanding at year-end and repaid in February 2021 |
| Operating cash flow | $0; formation costs were paid through equity issuance |
There were no meaningful revenue, profitability, margin, or cash-flow operations to analyze. The filing does not provide a prior comparable operating period because the company was newly incorporated.
After year-end, on January 29, 2021, the company completed an initial public offering of 20.7 million Class A shares at $10.00 per share, generating gross proceeds of $207.0 million, and sold 614,000 private-placement shares for $6.14 million. It placed $207.0 million in a trust account and reported total offering transaction costs of $11.93 million, including $7.245 million of deferred underwriting fees. Approximately $200.755 million was described as available for a business combination after estimated offering expenses and deferred underwriting fees.
The company expected the funds outside the trust account, together with potentially available sponsor or management loans, to fund operations through the business-combination period. The filing states that up to $1.5 million of working-capital loans could be converted into post-combination shares at $10.00 per share.
Material changes and unusual items
- The principal post-period event was the January 2021 IPO and private placement; these transactions did not occur during the December 31, 2020 reporting period.
- The company’s initial shareholders held 5.175 million Class B founder shares after a January 2021 share capitalization. Founder shares were designed to represent approximately 20% of the ordinary shares outstanding excluding private-placement shares after the IPO.
- The sponsor agreed to pay or reimburse up to $10,000 per month for office space and administrative support beginning January 26, 2021, continuing until the earlier of a business combination or liquidation.
- The company reported no off-balance-sheet arrangements, long-term leases, or material litigation.
- Management stated that substantial doubt about liquidity was alleviated after completion of the IPO, because capital outside the trust account was expected to support operations for at least one year.
Guidance, outlook, risks, and contingencies
Management’s objective was to complete an initial business combination within 24 months of the IPO closing, or by January 29, 2023. The target must generally have an aggregate fair market value of at least 80% of the assets held in the trust account, excluding deferred underwriting commissions and certain taxes, and the post-combination company must acquire a controlling interest in the target.
If no business combination were completed by the deadline, the company would cease operations, redeem the public shares using the trust-account proceeds, and liquidate. The anticipated redemption value was approximately $10.00 per public share, but could be lower because of creditor claims, negative investment returns, taxes, liquidation expenses, or other reductions in trust assets.
- There was no identified target, binding transaction, or assurance that a business combination would be completed.
- Public shareholders could redeem shares in connection with a business combination, subject to net tangible asset and other limitations. In a shareholder-vote scenario, holders generally could not redeem more than 15% of the public shares without company consent.
- The sponsor and management agreed to vote founder shares in favor of a proposed business combination if a shareholder vote were held and waived redemption rights for founder shares, private-placement shares, and certain public shares.
- The sponsor, HealthCor, Catalio, and affiliated entities had potential conflicts because they pursued other investments and could owe fiduciary or contractual duties to other entities.
- COVID-19 could adversely affect the search for a target, financing availability, capital markets, and the operations of a future target; the filing states that the specific financial impact was not determinable.
- Additional financing or debt might be required if redemptions were substantial or the selected transaction exceeded available cash. Additional securities could dilute public shareholders.
- The trust account could be subject to creditor claims despite attempted waivers. Sponsor indemnification was limited and the filing notes that the sponsor might not have sufficient assets to satisfy its obligations.
- Healthcare targets would face significant regulatory, reimbursement, intellectual-property, product-liability, research-and-development, and government-policy risks.
Most important facts for an investor to verify
- Verify the issuer identity: the supplied filing is for HealthCor Catalio Acquisition Corp. and does not appear to be a Hyperfine, Inc. filing.
- Verify whether the company ultimately completed a business combination by January 29, 2023 and identify the target, transaction terms, redemptions, financing, and post-combination ownership.
- Verify the actual trust-account balance and per-share redemption value, including deferred underwriting fees, interest, taxes, expenses, and creditor claims.
- Review dilution from founder-share conversion, private-placement shares, potential working-capital loans, sponsor financing, and any additional securities issued in the business combination.
- Assess sponsor and management conflicts, voting control, redemption waivers, related-party payments, and any post-combination compensation or registration rights.
- Confirm subsequent filings for audited financial statements, internal controls, liquidity, debt, and any material changes after the IPO.